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PURPOSE: Quality of life is a key element in the follow-up of people living
with HIV/AIDS. The main purpose of this study was to validate the French
version of the WHOQOL-HIV instrument by comparing this instrument to a
generic questionnaire. The second objective was to test the reproducibility of
this questionnaire. METHOD: The WHOQOL-HIV and SF-36 questionnaires were
filled out by 50 patients on two separate occasions with a time interval of 2
weeks. The internal consistency, validity and reliability of the WHOQOL-HIV were
evaluated. RESULTS: The internal consistency was acceptable for the different
domains, with Cronbach's alpha ranging from 0.937 to 0.944. The facet-domain
correlations were all statistically significant (p<0.001). There was a correlation
between the domains from the WHOQOL-HIV and SF-36 questionnaires, with
coefficients ranging from 0.349 to 0.763 (p<0.05 for all), except for the Spirituality
domain. The test-retest reliability was suitable for all domains and fa...
Document type : Article de périodique (Journal article)
Référence bibliographique
Reychler, Gregory ; Caty, Gilles ; Vincent, Anne ; Billo, Simon ; Yombi, Jean Cyr. Validation of
the French version of the World Health Organization quality of life HIV instrument. In: PLoS One,
Vol. 8, no. 9, p. e73180 [1-7] (2013)
DOI : 10.1371/journal.pone.0073180
Validation of the French Version of the World Health
Organization Quality of Life HIV Instrument
Gregory Reychler1,2,3*, Gilles Caty3, Anne Vincent4, Simon Billo3, Jean-Cyr Yombi4
1 Institut de Recherche Expe´rimentale et Clinique (IREC), Poˆle de Pneumologie, ENT & Dermatologie, Universite´ Catholique de Louvain, Brussels, Belgium, 2 Service de
Pneumologie, Cliniques universitaires Saint-Luc, Brussels, Belgium, 3De´partement de Me´decine Physique et Re´adaptation, Cliniques universitaires Saint-Luc, Brussels,
Belgium, 4Centre de prise en charge VIH, Cliniques universitaires Saint-Luc, Brussels, Belgium
Abstract
Purpose: Quality of life is a key element in the follow-up of people living with HIV/AIDS. The main purpose of this study was
to validate the French version of the WHOQOL-HIV instrument by comparing this instrument to a generic questionnaire. The
second objective was to test the reproducibility of this questionnaire.
Method: The WHOQOL-HIV and SF-36 questionnaires were filled out by 50 patients on two separate occasions with a time
interval of 2 weeks. The internal consistency, validity and reliability of the WHOQOL-HIV were evaluated.
Results: The internal consistency was acceptable for the different domains, with Cronbach’s alpha ranging from 0.937 to
0.944. The facet-domain correlations were all statistically significant (p,0.001). There was a correlation between the
domains from the WHOQOL-HIV and SF-36 questionnaires, with coefficients ranging from 0.349 to 0.763 (p,0.05 for all),
except for the Spirituality domain. The test-retest reliability was suitable for all domains and facets, with statistically
significant intra-class coefficients between 0.615 and 0.931.
Conclusion: This study demonstrated that the French translation of the WHOQOL-HIV instrument is a valid and reproducible
tool for the evaluation of the quality of life for HIV-infected patients.
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Introduction
Currently, UNAIDS estimates that more than 35 million people
are infected with human immunodeficiency virus (HIV) around
the world, and more than 10% of this population is living in
French-speaking countries [1].
It has been well established that in chronic diseases, an
emerging element is the evaluation of the quality of life (QoL)
[2]. Moreover, the QoL is a primary outcome of many studies [3].
Even though the overall HIV epidemic trends are declining, as
long as there is no curative treatment for HIV/AIDS, people will
continue to suffer from the disease, and measurement of the
quality of life will remain a key factor in the outcome of these
patients. Moreover, the life expectancy of HIV-infected patients
has increased due to the efficacy of highly active antiretroviral
treatment (HAART) [4]. With this enhancement of life expectan-
cy, people living with HIV/AIDS are facing more co-morbidities,
such as osteoporosis, cardiovascular disease and renal impairment.
The examination of the relationship between HIV infection and
the QoL has been increasingly studied over the last 10 years. For
example, the QoL was investigated in populations from different
countries [5–10] and in older adults with HIV infection [11]. The
QoL in HIV infection was also compared to the QoL in other
chronic diseases [12]. It has been reported that the QoL is related
to CD4+ cell counts [13,14], the onset of symptoms [12,14],
depression and stress [15,16] and antiretroviral treatment [17].
A reliable instrument to measure QoL is necessary, and many
generic questionnaires exist. In chronic diseases, there is a
particular need for disease-specific questionnaires evaluating the
QoL. Initially, the World Health Organization defined the
concept of the quality of life and developed a questionnaire to
specifically assess the quality of life for HIV-infected patients
(World Health Organization Quality of Life-HIV instrument
(WHOQOL-HIV)) [18]. The development of this questionnaire
was completed by a multi-centric pilot test in 8 different countries
[18–20].
The evaluation of the validity and reliability of this question-
naire is extremely important. Moreover, to be effective in a specific
country, such an instrument must be translated and validated in
the local language. Although this instrument was translated into
other languages [21–25], it has not been translated in French.
The aim of this study was to validate the French version of the
WHOQOL-HIV instrument by comparing this instrument to a
generic questionnaire. Furthermore, the test-retest reliability of the
French version was tested at 2 weeks.
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Materials and Methods
Ethics Statement
The study was approved by the regional Ethics Committee in
Cliniques universitaires Saint-Luc and Universite´ catholique de
Louvain in Brussels (B403201213334). All of the patients provided
written informed consent.
Subjects
HIV-infected patients regularly attending the outpatient infec-
tious disease clinic of Cliniques universitaires Saint-Luc were
recruited on a voluntary basis and without financial compensation
for this study. Consecutive patients fulfilling the inclusion criteria
were selected by the physician after approval of the patients to
enroll in the study until 50 patients were included in the second
part of the study.
The following inclusion criteria were used: 18 years or older,
infected with HIV for at least 6 months [26] and a native French
speaker (patients born in a francophone family speaking French at
home and living in the francophone part of Belgium). The patients
that were unstable (defined by any modification of health
outcomes) for the duration of the study were excluded from the
second phase of the study.
Protocol
The study included two phases. During the visit, the patients
received both questionnaires (WHOQOL-HIV and MOS 36-item
short form (SF-36)). They were asked to fill out these question-
naires while attending the consultation (Phase I). During this time,
they received a second package including the questionnaires with a
stamped and addressed reply envelope. They were asked to fill out
these questionnaires 15 days later and then send them back so that
the responses obtained during the initial visit could be compared
with the later responses (Phase II). If more than 20% of the items
were not filled out, the patient was excluded from the study.
Trained researchers were present to provide assistance in
completing the questionnaires if necessary.
Procedure
The process was based on Beaton’s guidelines [27]. The initial
WHOQOL-HIV instrument was translated from English into
international French using two bilingual translators with a medical
background whose primary language was French. Both French
translations were performed, and any resulting issues were
resolved. One independent translator translated this new version
back into English, and the translation was compared to the
original version. This translator was a native English speaker.
Questionnaires
WHOQOL-HIV. WHOQOL-HIV is a self-reported ques-
tionnaire. In the original version, socio-demographic information
regarding sex and age are obtained. The HIV-related information
includes the mode of transmission, HIV status and year of
diagnosis. General health status is evaluated by asking the subjects
to rate his or her health on the Likert scale, which ranges from
very poor (1) to very good (5). WHOQOL-HIV includes 120 items
and 37 important questions. The structure of the WHOQOL-HIV
questionnaire includes a profile with scores across six domains
(physical, psychological, level of dependence, social relationships,
environment and spirituality) and 29 facets, with 5 of these facets
relating to HIV/AIDS (symptoms of person living with HIV/
AIDS (PLWHA), social inclusion, forgiveness and blame, concerns
about the future, death and dying). Non-specific questions
concerning the subject’s overall QoL and health status are also
included. All of the items are rated on a five-point scale (not at all to
extremely for the intensity and capacity domains; never to always for
frequency; very dissatisfied to very satisfied or very good to very poor for
evaluation). For negatively framed items, the scores are reversed so
that the higher the score, the better the QoL. A score is calculated
from the facet and domain. Each item of a facet and facet of a
domain contribute equally to the facet and domain scores,
respectively.
MOS 36-item short form (SF-36). The SF-36 is an auto-
evaluation short-form health instrument [28,29] and was previ-
ously validated in French [30]. This form includes 36 items and
covers eight different scales: physical functioning (PF), role
limitations due to physical health problems (RP), bodily pain
(BP), general health perceptions (GH), vitality (VT), social
functioning (SF), role limitations related to emotional problems
(RE), and mental health (MH). A linear transformation on a 0 to
Table 1. Socio-demographic relatives and related-HIV
informations of the sample of patients.
Group test-retest
Gender
Male 32 (64.0)
Female 18 (36.0)
Education
None 0 (0.0)
Primary school 0 (0.0)
Secondary school 22 (44.0)
Second cycle 20 (40.0)
Third cycle 8 (16.0)
Marital status
Single 21 (42.0)
Married/Co-habiting 17 (34.0)
Separeted/Divorced 8 (16.0)
Widowed 4 (8.0)
Health status
Poor 2 (4.0)
Neither good nor poor 13 (26.0)
Good 27 (54.0)
Very good 8 (16.0)
HIV status
Asymptomatic 39 (78.0)
Symptomatic 3 (6.0)
AIDS 8 (16.0)
Treatment history
HAART 45 (90.0)
Untreated 5 (10.0)
Route of infection
Sexual intercourse with man 36 (72.0)
Sexual intercourse with woman 3 (6.0)
Drug use 1 (2.0)
Blood contamination 5 (10.0)
Other 5 (6.0)
Results are expressed by number of subjects (percentage).
doi:10.1371/journal.pone.0073180.t001
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100 scale (the lower the score, the worse the status) was performed.
The physical component summary (PCS) and mental component
summary (MCS) were also calculated by aggregating the 8
previous scales.
Statistical Analysis
The sample size needed (n= 52) to compare WHOQOL-HIV
to SF36 (Phase I) was determined by the method for studies
involving linear regression [31] with a power of 80.
The data were computed using SPSS 20.0 (IBM software) for
Windows. A descriptive analysis was performed for the socio-
demographic and HIV-related information. The internal consis-
tency was assessed using Cronbach’s alpha. The correlation
between the domains and overall quality of life was calculated for
WHOQOL-HIV. The validity was measured using Pearson
correlations to determine the strength of the relationship between
the scores for the hypothesised interrelated domains from the two
instruments and between each item and its domain for the
WHOQOL-HIV. The hypothesised interrelation was based on
two expert opinions. The experts were involved in quality of life
evaluation (CG) and in the follow-up of patients living with HIV/
AIDS (YJC) respectively. Their final decisions were based on their
own opinion and consensual. The test-retest reliability was
evaluated using an intra-class coefficient (ICC) for agreement,
and agreement was estimated using the Bland Altman method.
The correlations between the variables were measured using ICCs
[32–34]. The ICCs determine the extent of the relative
discrepancies between the evaluations and give the proportion of
Table 2. Descriptive scores for WHOQOL-HIV.
Mean SD Correlation Cronbach
Domain 1 _ Physical 14.60 3.57 – 0.942
Pain and discomfort 3.72 0.91 0.720 0.941
Energy and fatigue 3.48 0.92 0.843 0.940
Sleep and rest 4.00 1.00 0.632 0.941
Symptoms of PLWHAs 3.61 1.05 0.765 0.940
Domain 2 _ Psychological 14.89 2.54 – 0.937
Positive feelings 3.68 0.75 0.812 0.941
Cognitions 3.79 0.68 0.840 0.941
Self-esteem 3.63 0.69 0.842 0.941
Body image and appearance 3.70 1.01 0.722 0.941
Negative feelings 3.81 0.83 0.815 0.941
Domain 3 _ Level of independence 15.78 3.30 – 0.940
Mobility 4.23 0.88 0.751 0.941
Activities of daily living 4.10 0.81 0.844 0.940
Dependence on medication or treatment 3.40 1.36 0.705 0.941
Work capacity 4.04 1.04 0.905 0.940
Domain 4 _ Social relationships 14.74 2.54 – 0.940
Personal relationships 3.94 0.59 0.796 0.941
Social support 3.54 0.80 0.723 0.942
Sexual activity 3.40 1.03 0.731 0.941
Social inclusion 3.87 0.92 0.803 0.941
Domain 5 _ Environment 15.38 2.20 – 0.938
Physical safety and security 3.78 0.69 0.728 0.941
Home environment 3.89 0.84 0.760 0.941
Financial resources 3.37 1.08 0.735 0.941
Health and social care 4.19 0.57 0.542 0.942
New information or skills 3.92 0.71 0.633 0.942
Recreation and leisure 3.64 0.77 0.823 0.941
Physical environments 3.98 0.60 0.702 0.942
Transport 4.00 0.90 0.747 0.941
Domain 6 _ Spirituality 14.11 3.37 – 0.944
Spirituality, Religion, Personal beliefs 3.38 1.25 0.538 0.944
Forgiveness 3.81 1.07 0.713 0.941
Fear of the future 3.53 1.13 0.835 0.941
Death and dying 3.41 1.19 0.833 0.941
Overall QoL & general health perception 15.56 2.82 – 0.938
doi:10.1371/journal.pone.0073180.t002
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variance attributable to differences between the groups. The effect
size was calculated for each domain and item by taking the
difference between the mean baseline and follow-up scores on the
measurement and dividing by the standard deviation of the
baseline scores. All of the tests were two-tailed with a statistical
significance level fixed at a p value of 0.05.
Results
Among the 64 enrolled subjects in the first phase, 50 were
included in phase II of the study. The patients who were not
included either did not complete or did not return the
questionnaires or were hospitalised during this period. The
socio-demographic data of the patients are summarised in
Table 1. The age range of the patients was 20 to 66 years old
(mean age = 41.2610.9 yrs). The mean CD4+ cell count was
605.4/mm3. Eighty-four percent of the patients had undetectable
viral loads, and 90% of the patients were undergoing HAART.
Sixteen percent of the patients were classified as CDC stage C.
Neither questionnaire contained more than 20% of missing
responses.
The scores for the different facets and domains for the
WHOQOL-HIV instrument, correlations and internal consistency
values are presented in Table 2. WHOQOL-HIV demonstrated
acceptable internal consistency for the different domains, with
Cronbach’s alpha values ranging from 0.937 (Psychological) to
0.944 (Spirituality) (Table 2). The Cronbach’s alpha values were
acceptable for all of the facets (higher than 0.70) (Table 2). The
facet-domain correlations ranging between 0.538 and 0.905 were
all statistically significant (p,0.001) (Table 2).
The analysis of the score distribution in our patient population
revealed an absence of ceiling and floor effects for all of the
domains of WHOQOL-HIV with less than 15% of the patients
with a highest or lowest possible score, respectively. The ceiling
effects were nearly achieved (14%) for the item Overall QoL and
health status. No floor effects were observed, with less than 10% of
the patients having the lowest scores for all domains.
The results of the validation process revealed statistically
significant correlations between the overall quality of life and
different domains of WHOQOL-HIV, with all of the coefficients
ranging from 0.418 (Spirituality) to 0.735 (Environment). The
correlations between all of the domains for this instrument were
significant, with the exception of the correlation between Spirituality
and Environment (p = 0.119) (Table 3). Moreover, significant
correlations for all of the hypothesised interrelated domains
between SF-36 and WHOQOL-HIV were observed (Table 3).
The test-retest reliability contained statistically significant intra-
class coefficients for all of the domains and facets (Table 4)
(Figure 1). The Bland Altman method revealed a difference
between the measurement days for the domains (20.015 to 0.795)
and the facets (20.110 to 0.260). All of the differences were
included between the limits of agreement. Finally, the effect size
was small for all of the items and domains, varying from 0 to 0.36.
Discussion
Based on the distribution of scores for the WHOQOL-HIV
questionnaire, we report good internal consistency and validity.
Moreover, the test-retest validity was verified.
The internal consistency was excellent for all of the items and
domains, with Cronbach’s alpha scores ranging from 0.937 to
0.944. Internal consistency is classically considered acceptable for
Cronbach’s alpha between 0.70 and 0.95 [35]. Moreover, our
results are similar [21,36,37] or even better [25] than the
validations of this questionnaire in other languages.
Pearson’s correlation coefficients between individual items and
their respective domains were also calculated to assess the
structural validity of the questionnaire. Values greater than 0.30
are associated with an acceptable result [38]. The structural
validity of the questionnaire is very good, with all of the coefficients
higher than 0.50. Only the health and social care (0.542) and
spirituality, religion, personal beliefs (0.538) items showed a slightly
lower reliability than for the other items.
Ceiling and floor effects occur when 15% or more of the
patients respond with a highest or lowest score, respectively [39].
Similar to the Italian [24], Portuguese [21] and Brazilian [25]
versions, we did not observe these effects for any domain in our
patients. Therefore, the validity is acceptable with discriminative
extreme values.
The validity of the WHOQOL-HIV questionnaire is favour-
able. Indeed, the WHOQOL-HIV scores are related to the SF-36
scores for the interrelated domains. Even though a significant
correlation was found between spirituality and general health perception,
the hypothesised interrelationship between these two domains
should be discussed. The concepts included in the spirituality
domain are not fully integrated in the SF-36 questionnaire.
However, it has been previously demonstrated that the spirituality
item is not as important for HIV patients compared to other
components of the quality of life [21].
Table 3. Coefficients of correlation between domains of WHOQOL-HIV and SF-36.
WHOQOL-HIV SF-36
D1 D2 D3 D4 D5 D6 D suppl BP GH VT SF MH RE RP PF
D1 1 0.544 0.763
D2 0.662 1 0.703
D3 0.538 0.650 1 0.667 0.667 0.699
D4 0.394 0.660 0.595 1 0.511
D5 0.565 0.695 0.723 0.660 1 0.595
D6 0.521 0.537 0.355 0.320 0.224 1 0.540
D suppl 0.613 0.714 0.683 0.677 0.735 0.418 1 0.583
D1= physical domain, D2 = psychological domain, D3 = independence domain, D4 = social domain, D5 = environment domain, D6 = Spirituality, D suppl =Overall QoL,
BP = bodily pain, GH=general health perceptions, VT = vitality, SF = social functioning, MH=mental health, RE = role emotional, RP = role physical, PF = physical
functioning.
doi:10.1371/journal.pone.0073180.t003
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Figure 1. Relationship between scores of domains for test-retest WHOQOL-HIV.
doi:10.1371/journal.pone.0073180.g001
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The test-retest reliability was evaluated by an intra-class
coefficient for agreement, which is the most suitable reliability
parameter [35] and more adequate than the intra-class coefficient
for consistency [32]. Both instruments were administered again at
two weeks. Two weeks is a time period that is long enough to
prevent the patients from remembering the previous test but short
enough to avoid changes in health status. As a value of 0.70
represents the minimum standard for reliability [40], our results
demonstrated a good test-retest reliability for all of the domains.
Moreover, using the Bland and Altman method, our results reveal
a bias lower than 0.800 for all of the domains. The Bland and
Altman method [41] is an adequate method to observe absolute
measurement errors between two repetitive tests [35].
The effect size is defined as small (ES ,0.2), small to moderate
(ES between 0.2 and 0.5), moderate to large (ES between 0.51 and
0.79), and large (ES .0.79) [42]. The effect size is a simple way to
quantify the size of the difference between two measurements. In
our study, nearly all of the effect sizes were lower than 0.2. Only
three effect sizes were between 0.2 and 0.4. These results highlight
good agreement between the measurements.
Table 4. Results for the WHOQOL-HIV at day 1 and day 15 and intra-class coefficient (ICC) for the different items and domains of
the WHOQOL-HIV for the test-retest validation.
WHOQOL-HIV day 1 WHOQOL-HIV day 15 Mean bias
Limits of
agreement ICC
Mean SD Mean SD Mean SD Low High
Domain 1 _ Physical 14.60 3.57 14.61 3.58 20.015 2.274 24.472 4.442 0.798
Pain and discomfort 3.72 0.91 3.76 0.99 20.045 0.550 21.123 1.033 0.832
Energy and fatigue 3.48 0.92 3.40 0.98 0.075 0.382 20.674 0.824 0.919
Sleep and rest 4. 00 1.00 3.88 1.03 0.120 0.637 21.129 1.369 0.802
Symptoms of PLWHAs 3.61 1.05 3.57 1.18 0.035 0.747 21.430 1.500 0.776
Domain 2 _ Psychological 14.89 2.54 14.70 2.67 0.192 1.249 22.257 2.641 0.885
Positive feelings 3.68 0.75 3.61 0.69 0.075 0.563 21.028 1.178 0.696
Cognitions 3.79 0.68 3.72 0.64 0.070 0.385 20.684 0.824 0.828
Self-esteem 3.63 0.69 3.57 0.67 0.060 0.470 20.861 0.981 0.761
Body image and appearance 3.70 1.01 3.70 1.06 0 0.578 21.133 1.133 0.845
Negative feelings 3.81 0.83 3.79 0.96 0.025 0.426 20.811 0.861 0.887
Domain 3 _ Level of independence 15.78 3.30 14.98 3.51 0.795 1.925 22.978 4.568 0.840
Mobility 4.23 0.88 4.04 0.97 0.185 0.701 21.190 1.560 0.715
Activities of daily living 4.10 0.81 3.99 0.87 0.110 0.485 20.840 1.060 0.835
Dependence on medication or treatment 3.40 1.36 3.14 1.48 0.260 1.184 22.062 2.582 0.652
Work capacity 4.04 1.04 3.82 0.99 0.220 0.686 21.125 1.565 0.770
Domain 4 _ Social relationships 14.74 2.54 14.54 2.41 0.205 1.361 22.462 2.872 0.849
Personal relationships 3.94 0.59 3.72 0.65 0.215 0.395 20.558 0.988 0.796
Social support 3.54 0.80 3.55 0.78 20.015 0.686 21.359 1.329 0.624
Sexual activity 3.40 1.03 3.37 0.98 0.030 0.658 21.259 1.319 0.786
Social inclusion 3.87 0.92 3.90 0.86 20.025 0.635 21.270 1.220 0.744
Domain 5 _ Environment 15.38 2.20 15.31 2.15 0.073 0.951 21.791 1.936 0.905
Physical safety and security 3.78 0.69 3.81 0.76 20.030 0.573 21.153 1.093 0.690
Home environment 3.89 0.84 3.82 0.72 0.060 0.453 20.829 0.949 0.833
Financial resources 3.37 1.08 3.34 0.99 0.020 0.494 20.949 0.989 0.886
Health and social care 4.19 0.57 4.20 0.53 20.020 0.448 20.899 0.859 0.665
New information or skills 3.92 0.71 3.95 0.63 20.025 0.587 21.176 1.126 0.615
Recreation and leisure 3.64 0.77 3.57 0.74 0.060 0.526 20.971 1.091 0.756
Physical environments 3.98 0.60 3.80 0.63 0.180 0.388 20.581 0.941 0.802
Transport 4.00 0.90 4.11 0.79 20.110 0.547 21.182 0.962 0.793
Domain 6 _ Spirituality 14.11 3.37 13.86 3.67 0.240 1.308 22.324 2.804 0.931
Spirituality, Religion, Personal beliefs 3.38 1.25 3.30 1.29 0.070 0.567 21.041 1.181 0.900
Forgiveness 3.81 1.07 3.60 1.13 0.200 0.732 21.235 1.635 0.777
Fear of the future 3.53 1.13 3.54 1.16 20.005 0.538 21.060 1.050 0.889
Death and dying 3.41 1.19 3.42 1.26 20.015 0.644 21.277 1.247 0.862
Overall QoL & general health perception 15.56 2.82 15.10 2.84 0.460 1.876 23.217 4.137 0.781
All ICC are statistically significant (p,0.001).
doi:10.1371/journal.pone.0073180.t004
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The limitation of this study is that the sample better reflects the
quality of life for patients followed in a health care centre rather
than other patients. However, the characteristics of the sample are
comparable to the Belgian HIV population according to the last
report from the Belgian Scientific Institute of Public Health (2010)
[43]. The ratio between men and women who took part in the
study is 1.77 compared to 1.7 in the Belgium population of HIV-
infected patients, and the CD4+ T cell counts are greater than the
mean Belgian levels. Moreover, the mean age and percentage of
treated patients are only slightly higher (37.6 vs 41.2 yrs and 80 vs
90%, respectively) than the global population in our centre.
Finally, responsiveness remains to be tested. However, all of the
psychometric properties of a scale cannot be established in a single
study [44].
In conclusion, the French version of WHOQOL-HIV is valid
for the evaluation of the quality of life for HIV patients. This
questionnaire correlates with a well-validated questionnaire (SF-
36). Moreover, the French version of WHOQOL-HIV is a reliable
tool with good reproducibility within a two-week period.
Specificity and sensitivity have been previously demonstrated [36].
The French version of the questionnaire can be downloaded
here: http://www.saintluc.be/services/medicaux/vih/
WHOQOL-HIV-questionnaire.pdf.
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